

# China National Accord Medicines Corporation Ltd.

## Summary of Semi-Annual Report 2021

### I. Important Notice

The summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details, investors should carefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and Shenzhen Stock Exchange Website etc., appointed by CSRC.

Other directors attending the Meeting for semi-annual report deliberation except for the followed

Name of director absent	Title for absent director	Reasons for absent	Attorney
-------------------------	---------------------------	--------------------	----------

Prompt of modified auditing opinion

Applicable  Not applicable

Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting period

Applicable  Not applicable

The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reserves

Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period

Applicable  Not applicable

### II. Basic information of the company

#### 1. Company profile

Short form of the stock	Sinopharm Accord, Accord B	Stock code	000028, 200028
Stock exchange for listing	Shenzhen Stock Exchange		
Person/Way to contact	Secretary of the Board	Rep. of security affairs	
Name	Chen Changbing	Wang Zhaoyu	
Office add.	Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province	Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province	
Tel.	+ (86) 755 25875195	+ (86) 755 25875222	
E-mail	gyzinvestor@sinopharm.com	gyyz0028@sinopharm.com	

#### 2. Main financial data and index

Whether it has retroactive adjustment or re-statement on previous accounting data

□ Yes √ No

	Current Period	Same period of last year	Increase/decrease in this report y-o-y
Operating revenue (RMB)	33,163,091,887.39	27,169,940,188.52	22.06%
Net profit attributable to shareholders of the listed Company (RMB)	741,445,013.25	643,451,580.59	15.23%
Net profit attributable to shareholders of the listed Company after deducting non-recurring gains and losses (RMB)	720,954,408.22	627,017,019.45	14.98%
Net cash flow arising from operating activities (RMB)	1,229,373,283.57	1,438,204,043.35	-14.52%
Basic earnings per share (RMB/Share) (note 1)	1.73	1.50	15.33%
Diluted earnings per share (RMB/Share)	1.73	1.50	15.33%
Weighted average ROE	5.22%	4.91%	Increase 0.31 percentage points
	End of current period	End of last period	Increase/decrease in this report-end over that of last period-end (+,-)
Total assets (RMB)	44,190,878,403.95	39,594,533,471.65	11.61%
Net assets attributable to shareholder of listed Company (RMB)	14,346,870,065.79	13,948,322,652.33	2.86%

### 3. Number of shareholders and share-holding

Unit: share

Total common shareholders at period-end		43,600	Total preference shareholders with voting rights recovered at end of reporting period (if applicable)		0	
Top ten shareholders						
Full name of Shareholders	Nature of shareholder	Proportion of shares held	Amount of shares held	Amount of restricted shares held	Information of shares pledged, tagged or frozen	
					State of share	Amount
Sinopharm Group Co., Ltd.	State-owned Corporation	56.06%	239,999,991	5,505,770		
FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND	Foreign Corporation	2.68%	11,469,644			
Hong Kong Securities Clearing Company Ltd	Foreign Corporation	2.58%	11,033,948			

China National Pharmaceutical Foreign Trade Corp.	State-owned Corporation	1.24%	5,323,043			
National Social Security Fund 413 Portfolio	Domestic non state-owned Corporation	0.98%	4,200,032			
BBH BOS S/A FIDELITY FD - CHINA FOCUS FD	Foreign Corporation	0.78%	3,358,761			
China Construction Bank Corporation -China Europe Value Discovery Equity Fund	Domestic non state-owned Corporation	0.73%	3,111,875			
CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan	Domestic non state-owned Corporation	0.66%	2,822,801			
Fidelity Investment Management (Hong Kong) Limited - Client's fund	Foreign Corporation	0.54%	2,308,237			
VANGUARD EMERGING MARKETS STOCK INDEX FUND	Foreign Corporation	0.41%	1,756,387			
Explanation on associated relationship among the aforesaid shareholders	Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies.					

#### 4. Changes of controlling shareholders or actual controller

Changes of controlling shareholders in reporting period

Applicable  Not applicable

Changes of controlling shareholders had no change in reporting period.

Changes of actual controller in reporting period

Applicable  Not applicable

Changes of actual controller had no change in reporting period.

**5. Total preferred stock shareholders of the Company and shares held by top ten shareholders with preferred stock held**

Applicable  Not applicable

The Company had no shareholders with preferred stock held in the reporting.

**6. Bonds in existence as of the approval date of the semi-annual report**

Applicable  Not applicable

**III. Important events**

Nil